{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:19:15Z","timestamp":1782573555325,"version":"3.54.5"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,9]]},"abstract":"<jats:p>To investigate biometric and refractive results in patients with type 1 retinopathy of prematurity (ROP) treated by intravitreal injection (IVI) of ranibizumab (R) and bevacizumab (B) at the corrected age of 6. This is a single-center retrospective study. Infants diagnosed with type 1 ROP and treated with IVI of either R or B as the primary therapy were included. Data on axial length, anterior chamber depth (ACD), and lens thickness (LT) were obtained using A-scan ultrasound. Cycloplegic refraction, keratometry (K), and best-corrected visual acuity were also documented. Additionally, optical coherence tomography angiography was performed to assess the foveal avascular zone and the density of superficial and deep vessels. We analyzed the structural and functional differences between the 2 groups and compared them with findings from a previous study conducted when these children were between the ages of 1 and 3. The study included 60 eyes from 34 patients, with 34 eyes receiving B and 26 eyes receiving R injections for ROP. In biometric outcomes, there was still a deeper ACD (3.36\u2005\u00b1\u20050.24\u2009mm in the B group; 3.52\u2005\u00b1\u20050.21\u2009mm in the R group) and thinner LT (3.63\u2005\u00b1\u20050.16\u2009mm in the B group; 3.53\u2005\u00b1\u20050.12\u2009mm in the R group) in the R group, as previously reported at the age of 3. In the refractive aspect, the eyes treated with B had higher myopia at the ages of 1 and 3; however, at the age of 6, refractive errors did not differ significantly between the 2 groups. At the corrected age of 6, the eyes treated with IVI of R were associated with deeper ACD and thinner LT. Interestingly, the emmetropization process resulted in a similar incidence of high myopia at the age of 6, which was different from the outcomes observed at younger ages.<\/jats:p>","DOI":"10.1097\/md.0000000000039251","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T18:36:59Z","timestamp":1723228619000},"page":"e39251","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Six years follow-up of type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of ranibizumab and bevacizumab: Long-Term Outcomes of intravitreal injection in Type 1 ROP"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2800-0323","authenticated-orcid":false,"given":"Hsiao-Fan","family":"Tung","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, China Medical University Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ling","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Surgery, Clinical Research Center, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Chih","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Lin","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Changhua Christian Hospital, Changhua, Taiwan"},{"name":"Department of Nursing, College of Nursing and Health Sciences, Da-Yeh University, Changhua, Taiwan"},{"name":"Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0871-381X","authenticated-orcid":false,"given":"San-Ni","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, China Medical University Hospital, Taichung, Taiwan"},{"name":"Department of Optometry, Da-Yeh University, Changhua, Taiwan"},{"name":"Department of Medicine, School of Medicine, Chung-Shan Medical University, Taichung, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments.","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/bjophthalmol-2019-314610","article-title":"Foveal microvasculature, refractive errors, optical biometry and their correlations in school-aged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation.","volume":"104","author":"Chen","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis.","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity.","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"4565216","DOI":"10.1155\/2018\/4565216","article-title":"Refractive and biometric outcomes in patients with retinopathy of prematurity treated with intravitreal injection of ranibizumab as compared with bevacizumab: a clinical study of correction at three years of age.","volume":"2018","author":"Chen","year":"2018","journal-title":"J Ophthalmol"},{"key":"R9-20250503","first-page":"233","article-title":"Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial.","volume":"102","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.","volume":"35","author":"Chen","year":"2015","journal-title":"Retina"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:37:07Z","timestamp":1746319027000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":10,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039251","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]}}}